As a healthcare provider, you know the best decisions are informed decisions. That’s why you use a variety of tools to monitor patients throughout their pregnancies. Genetic testing is helpful to reassure patients, and guide you when risks arise.
For the Avero Prenatal Screen, cell-free DNA (cfDNA) is analyzed from a maternal blood sample to assess the pregnancy for common chromosome aneuploidies, including trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and sex chromosome abnormalities. This noninvasive screen offers providers and their patients accurate information about the risk for these conditions during pregnancy, as early as 10 weeks’ gestation.